BioMed Nexus Daily Updates
Your essential biotech, medtech, and pharma recap — no noise, just what matters.
⚡ Executive Takeaway
BridgeBio's "best-in-indication" Phase 3 dwarfism data has triggered an immediate competitive repricing for BioMarin and Ascendis, raising switching pressure toward an oral therapy, pending full data and label details. Simultaneously, the FDA's aggressive move to remove "Boxed Warnings" from hormone replacement therapy (HRT) signals a notable shift in how the FDA communicates benefit-risk for menopausal hormone therapy. 👉 Read More
📅 Week Ahead
Mon 2/16: President's Day (Markets Closed).
Tue 2/17: Medtronic (MDT) Earnings (Watch for Symplicity renal denervation adoption).
Wed 2/18: Analog Devices (ADI) Earnings (healthcare sensor demand signal).
🔮 What To Watch
The Dwarfism "Switch" Trade With BridgeBio's infigratinib achieving a +2.10 cm/year growth velocity (superior to BioMarin's historical benchmarks), watch for a mass patient rotation from daily injections to daily pills. This threatens the multi-billion dollar injectable market currently held by Voxzogo. 👉 Read More
Pan-Flu Benchmarking Centivax's Phase 1 "Universal Flu" start is a long-horizon attempt to disrupt the seasonal reformulation cycle, with Phase 1 data as the first credibility test. If successful, it could challenge the annual vaccine model. 👉 Read More
Medicaid Cost-Sharing Volatility New Medicaid rules taking effect in "sanctuary" states like California (amid a $600M CDC funding freeze) may force health systems to absorb higher uncompensated care costs in 1H 2026. 👉 Read More
🚀 Today's Top Story
BridgeBio Crushes Achondroplasia Phase 3; Teases "Best-In-Indication" Growth
What Happened: BridgeBio (BBIO) announced positive topline Phase 3 PROPEL 3 results for oral infigratinib. The drug achieved a statistically significant annualized height velocity (AHV) difference of +1.74 cm/year (LS mean) over placebo (p<0.0001)—with an unadjusted mean difference of +2.10 cm/year.
The "Wow" Factor: Crucially, it showed the first-ever statistically significant improvement in body proportionality in children under 8 years old.
Why It Matters: Analyst commentary suggests infigratinib outperformed the historical pivotal benchmarks of BioMarin's Voxzogo and Ascendis' TransCon CNP. As an oral pill, it removes the "injection burden" that currently limits pediatric compliance.
Executive Impact: BioMarin (BMRN) and Ascendis (ASND) must now defend their injectable franchises against an oral competitor with superior growth data. BridgeBio intends to file NDA/MAA in 2H 2026.
🎗️ Oncology & Rare Disease
Novocure (FDA Approval)
Approval: The FDA approved Optune Pax yesterday, a portable, non-invasive device for locally advanced pancreatic cancer—the first new treatment approved for this indication in nearly 30 years.
Data: Adding Tumor Treating Fields (TTFields) to standard chemo (GnP) improved overall survival by approximately 2 months (16.2 vs 14.2 months; p=0.039). 👉 Read More
Ultragenyx (Restructuring)
Pivot: Reported 2025 revenue of $673M but announced a strategic restructuring, including a 10% workforce reduction (~130 employees), to focus resources on its Angelman syndrome Phase 3 readout (H2 2026). 👉 Read More
🔬 Clinical & Research Updates
Annovis Bio (Alzheimer's)
Clearance: An independent DSMB cleared Annovis to continue its Phase 3 trial of buntanetap without changes, citing a clean safety profile across the first 40% of enrolled patients. 👉 Read More
Centivax (Universal Flu)
Milestone: Dosed the first participant yesterday in a Phase 1 trial for Centi-Flu 01. Unlike seasonal shots, it targets "conserved" viral regions that do not mutate, aiming for permanent, pandemic-proof immunity. 👉 Read More
EMA Regulatory Shift
Policy: The EMA continues to tighten active substance manufacturing controls following ongoing detections of nitrosamine impurities, signaling an intensifying "zero-tolerance" policy for carcinogenic contaminants. 👉 Read More
🏢 Corporate Developments
Seres Therapeutics (Reboot)
Cuts: The microbiome pioneer announced a 30% workforce reduction and paused its lead program (SER-155) to pivot toward earlier-stage immunology research, extending its cash runway into Q3 2026. 👉 Read More
Samsung Bioepis (Settlement)
Deal: Settled with Regeneron yesterday to secure a January 2027 U.S. launch for its Eylea biosimilar (Opuviz), providing the market with a definitive timeline for the next major "biologic-to-biosimilar" rotation. 👉 Read More
🌍 Policy & Public Health
FDA HRT De-risking
Action: In a landmark move, the FDA removed "Boxed Warnings" for cardiovascular disease, breast cancer, and dementia from six menopausal hormone therapies.
Quote: Commissioner Makary stated the agency is "delivering on our promise to make sure women have accurate, scientifically grounded information... free from exaggeration." 👉 Read More
CDC Funding Freeze
Legal: A U.S. District Court granted a 14-day temporary restraining order yesterday, blocking the administration from terminating approximately $600M in CDC grants to California, Colorado, Illinois, and Minnesota. 👉 Read More
🔒 BioMed Nexus Pro — Institutional Intelligence Brief
In Today's Pro Brief:
🧠 The "Makary FDA" Alpha: Why the HRT label change triggers a repricing for "Lifestyle Science" assets.
⚖️ Seres (MCRB) Distress: The 30% cut buys time, but is it enough? We analyze the Q3 2026 cash cliff.
🧮 BridgeBio Valuation: The market is pricing in a 40% switch rate from Voxzogo. We check the math.
